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The first devices to be developed for the delivery of bronchodilators and corticosteroids for the treatment 
of asthma were the pressurised metered dose inhalers (pMDIs). While pMDIs are viewed as patient 
friendly, they are associated with some serious disadvantages, such as considerable oropharyngeal 
deposition (due to the speed of delivery of the dose) and poor patient co-ordination of inhalation and 
activation. This has resulted in the development of alternative systems, such as the dry powder inhaler 
(DPI). However, DPIs also have problems, as there are difficulties in handling, measuring and metering 
fine particles. New devices, such as the Easi-breathe@ and Diskus@ inhalers, are now being introduced 
to overcome some of these problems. The ideal device is one that will produce a large proportion of 
respirable particles in the emitted dose. It must also deliver precise and uniform doses of drug to the 
patient. Further innovations are required to achieve these goals. 
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Introduction 
When Dr Mark Everard, Consultant Paediatrician at 
Sheffield Children’s Hospital, addressed the sympo- 
sium ‘A Question of Asthma’ at the British Pharma- 
ceutical Conference last year, he observed that the 
dose of a drug reaching the lung bore little relation to 
the nominal or prescribed dose. The lowest appar- 
ently effective dose should, therefore, be used. How- 
ever, it would be preferable to be able to improve the 
clinical outcome by improving the precision of the 
administered drug dose. To achieve this, three inter- 
acting factors must be considered: the patient, the 
formulation, and the device. 
The device must accurately meter the drug dose. 
Since this dose must be satisfactorily delivered during 
the inspiratory process, the total entrainment of the 
drug is also important. Finally, all the particles in the 
delivered dose must be of an appropriate size for 
deposition. 
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Pressurised Metered Dose Inhalers 
(pMDI4 
pMDIs have various advantages, including high 
market appeal and the energy within the formula- 
tion (i.e. the propellant which creates the respirable 
particles). They are portable and unobtrusive. How- 
ever. these devices are also associated with some 
serious disadvantages. As the particles are produced 
by internal energy they travel very fast, resulting in 
impaction in the oropharynx and reducing the dose 
reaching the lung. Furthermore, pMDIs cannot be 
used for large drug doses. Another disadvantage is 
poor patient co-ordination (see below). In addition, 
formulation with non-chlorofluorocarbon (non- 
CFC) propellants (hydrofluoroalkane; HFA) has 
also proved to be difficult. For example, some 
HFA formulations of beclomethasone dipropionate 
(BDP) use ethanol to solubilise the drug and the 
end process is atomisation of a solution rather than 
a suspension stabilised by surfactants (as in most 
CFC pMDIs). The mean particle size is <2pm, 
whereas established CFC formulations (in which the 
particle size is determined primarily by the extent to 
which the active ingredient can be milled) have an 
average particle size of 3 to 4pm. 
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TABLE 1. Incidence of patient misuse of pMDIs 
Reason Incorrect use (%) 
Remove cap 7 
Shake inhaler 43 
Breathe out 29 
Position in mouth 29 
Slow inhalation 64 
Actuate at start 57 
Continue to inhale 46 
Hold breath 43 
Exhale slowly 5 
These new formulations also produce a very dif- 
ferent particle size distribution, with the result that 
only 50 or even 25,~g of BDP is required compared 
with 100 pug from conventional pMDIs. In addition, 
because of the larger proportion of small particles 
in the HFA BDP formulation, around 20% of the 
dose from the new formulation is exhaled and there 
is high alveolar exposure, which does not occur with 
conventional pMDIs. 
Clinicians are very familiar with patient misuse of 
pMDIs (Table 1). Indeed, many hours are spent 
counselling patients how to use these devices cor- 
rectly. While this has resulted in formal, consultative, 
advisory counselling activities, which will improve the 
situation with pMDIs, the question of incorrect use 
remains a problem. Misuse is being addressed with 
new devices, such as the Easi-Breathe@ inhaler. The 
aim of this device is to improve the co-ordination 
\ 
\ 
\ 
between dose generation, which is an intrinsic part of 
the device, and the inspiration process. 
A different principle is used in the Spacehaler@. 
This device captures large, fast-moving particles 
within a modified actuator, giving a smaller dose of 
slow-moving, deeply respirable particles. 
Although such developments will help to sustain 
the future place of pMDIs, the intrinsic disadvantages 
of these devices have stimulated the development of 
alternative systems. 
Dry powder inhalers (DPIs) 
One of the difficulties facing the development of 
formulations for powder systems is that drugs that 
are fine enough to deposit within the lung are very 
difficult to handle, measure and meter. Consequently, 
such drugs have to go through an aggregation pro- 
cess, which usually involves binding the drug to a 
carrier, such as lactose. As the material passes 
through the device during inhalation, a proportion of 
the drug de-aggregates to create respirable particles 
(Fig. 1). This proportion is typically quite low 
(around lo-20%), and there is still significant oro- 
pharyngeal deposition, because most of the drug 
remains associated with large carrier particles. How- 
ever, DPIs do have one intrinsic advantage in that the 
de-aggregation process is generated by patient 
inspiration. There is, therefore, natural co-ordination 
between generation of the aerosol cloud and inspira- 
tion, but the quality of the cloud will depend on the 
patient. 
Some early, but important, work on the delivery 
of sodium cromoglycate in volunteers using a 
i 
Dispersion device 
‘Dispersed’ aerosol 
FIG. 1. De-aggregation of drug from carrier by passage through a dispersion device to produce the ‘dispersed 
aerosol. Only a proportion of the drug + carrier is de-aggregated to create respirable particles. 
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FIG. 2. The effect of terbutaline (250,& at different 
inhalation rates on the forced expiratory volume in 
1 second (FEV,) in children. 
Spinhaler@ demonstrated that the dose of drug deliv- 
ered to the lung is much higher with greater peak 
inspiratory flow rates (1). Using a Turbuhaler@, 
Pedersen et al. (2) studied the delivery of terbutaline 
(250,~~g) in children using different inspiration rates. 
This study showed that clinical response improved as 
the inspiration rate (and presumably the number of 
respirable particles) increased. (Fig. 2). 
Borgstrom et al. (3) investigated the clinical rel- 
evance of the variability in dose produced from the 
Turbuhaler@. The variability of the emitted dose was 
much higher with the Turbuhaler@ than with the 
pMD1 (Table 2), which produces very precise doses. 
Despite this, the Turbuhaler@ resulted in much 
higher pulmonary availability than the pMDI(l9.5 vs 
6.3% of nominal dose). Thus, the basic principle of 
generating the aerosol cloud by the inspiration pro- 
foundly affected the clinical efficacy of the two 
devices. Unlike the pressurised system, the DPI is 
therefore capable of important refinement. This study 
also showed that there were improvements in intra- 
and inter-patient variability with the powder inhaler 
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compared with the pMD1 (3) arising from the 
co-ordination of dose generation and inspiration. 
Early examples of powder inhalers include the 
Spinhale@, Rotahaler@ and Berote@ inhaler. The 
simple pre-metered DPI, such as the Spinhaler@, uses 
a capsule. While such devices have some advantages, 
such as good dose uniformity, compact size, dose 
protection, no dose size limitation (20-30 mg can be 
given, if necessary) and low cost, they are not very 
patient friendly. 
An important development in the use of powder 
inhalers is the reservoir DPI, for example, the 
Turbuhaler@. Reservoir DPIs are much closer in 
concept to pMDIs. However, reservoir DPIs also 
have disadvantages, including problems with dose 
uniformity, complexity and cost. They are also 
moisture sensitive and are generally dose limited by 
the size of the reservoir. 
There is, therefore, an interesting balance between 
pre-metered and reservoir dry powder systems, and 
the best aspects of both have been incorporated in the 
Diskus@ (the Accuhaler@ in the UK and some other 
countries). This device maintains the advantages of 
the pre-metered system while incorporating multiple 
doses. One important aspect of DPIs is dose protec- 
tion. It is extremely difficult to protect powders in 
device reservoirs as they are particularly susceptible 
to humidity, but the Diskus@ has overcome this 
problem, the doses being factory dispensed in sealed 
blisters. 
The ideal inhaler 
The ideal inhaler is a device in which at least 80% of 
the emitted dose consists of respirable particles. It 
must also deliver precise and uniform doses of the 
drug to the patient. 
Formulation 
In refining a formulation, process conditions, carrier 
size, drug : carrier ratio, and tertiary components can 
TABLE 2. Insulin bioavailability is dependent on regional deposition in the lung. 
Species Penetration index 
Reference (number) (P:C) LAmin) F (“A) 
Colthorpe et al. (4) Rabbit (4) 0.3 11 5.6 
1.5 12 57 
Pillai et al. (5) Rhesus monkey (6) 1.6 1 O-20 63 
3.1 1 O-20 Approx. 100 
Abbreviations: P = peripheral; C = central; t,,, = time to maximum plasma concentration; 
F = bioavailability. 
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be altered, and surfaces modified. A recent example is 
the ‘passivation’ of a carrier substrate surface. The 
theory of adhesion of small particles to large particles 
suggests that there are areas of high and low activity, 
and in this case, leucine is added as an adhesion- 
modifying tertiary component. This greatly enhances 
the ability of the energy from the patient’s inspiration 
to displace active drug particles, thus increasing the 
effective dose. 
There may, however, be limitations in the way in 
which formulations can be improved to generate 
efficient devices. There may be a future for DPIs in 
which the energy for de-aggregation is built into the 
device. One of the most advanced devices of this type 
is the Dura Spires@ inhaler, which uses electronic/ 
mechanical means to generate the cloud and 
co-ordinate inspiration with operation. 
Drug 
Clearly, the drug is a very important factor influ- 
encing delivery to the lung. Its size, surface mor- 
phology and adhesiveness can be controlled by 
refined fluid energy milling, spray drying and other 
novel techniques. The method by which fine particles 
are produced for pulmonary delivery is a major 
limitation of the efficacy of formulations and devices. 
Nevertheless, the range of techniques available offer 
different methods for producing particles of appropri- 
ate sizes and surface characteristics. As a result, much 
remains to be achieved with DPIs before their full 
contribution to pulmonary delivery is realised; this 
contrasts with pMDIs, which appear to be more fully 
developed. It will be interesting to see if this proves to 
be the case, particularly as new HFA formulations 
are introduced. 
Other devices 
Alternative device technologies are also being devel- 
oped. It is generally accepted that it is easier to 
sub-divide a liquid than a solid into very fine parti- 
cles. Traditionally, this has been achieved using 
nebulisers, which have their own place in clinical 
practice. Nebulisers have the advantage that the 
particles are entrained at the speed of respiration, 
resulting in efficient delivery. However, many uncer- 
tainties surround the performance of nebulisers and 
at present, fine particle dose is determined by the 
particular nebuliser and its operation. Further key 
developments are anticipated. 
One such development is the AER@ dosage form, 
which nebulises a liquid by forcing it, under pressure, 
through an array of fine holes to produce a fine spray 
with a carefully controlled particle size. The Bineb@ 
device uses a similar process. At present, most effec- 
tive systemic delivery using the pulmonary route, 
based on new technologies, are being derived from 
nebuliser systems. Studies with such innovations have 
shown the importance of regional deposition and 
distribution pattern, i.e. penetration index, the ratio 
of peripheral to central deposition (Table 2). Finer 
particles result in much deeper lung penetration, as 
reflected by the change in the penetration index (4,5). 
Comparison of blood levels after pulmonary delivery 
with those following either subcutaneous or intra- 
venous administration showed that systemic avail- 
ability depended on the penetration index and that 
almost total systemic availability was possible. This 
suggests that if the precision of pulmonary delivery 
is radically improved, greater exploitation of the 
concept of targeting drugs to the lung becomes 
possible. 
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